Against a backdrop of crippling economic constraints and a steadily tightening U.S. economic, commercial, and financial blockade, Cuba has marked a major milestone in protecting public health: the full restart of production at the AICA Laboratories cytostatic drug facility, following a targeted expansion investment designed to boost domestic output of critical cancer treatments.
The reopening event, held on June 5, 2026, brought together senior leaders from Cuba’s biopharmaceutical sector and public health system, including BioCubaFarma president Mayda Mauri Pérez, who hosted Minister of Public Health José Angel Portal Miranda during an official tour of the upgraded facility. The visit underscored the close cross-sector collaboration between the national biopharmaceutical industry, the Ministry of Public Health (Minsap), and the Cuban government – a partnership that officials say was instrumental to completing the expansion and restart despite the country’s ongoing external pressures.
Per an official update shared to BioCubaFarma’s Facebook page, the production restart is being carried out as a gradual, carefully monitored process. Each stage of manufacturing will be brought online incrementally, a deliberate approach chosen to guarantee consistent technological stability and adherence to Cuba’s strict quality standards for pharmaceutical products.
Following the expansion, the upgraded plant is now positioned to supply 16 different cytostatic (cancer-fighting) medications to Cuba’s National Program for the Care of Cancer Patients. Production scheduling has been structured to prioritize the drugs classified as most clinically critical, aligned with needs assessments coordinated directly with Minsap.
Speaking during the reopening ceremony, Portal Miranda emphasized that even amid widespread economic limitations, the facility’s return to operation represents a critical step forward in securing consistent access to life-saving cancer treatments for the Cuban people. Mayda Mauri Pérez echoed this sentiment, noting that the intersectoral alliance between the biopharmaceutical and public health sectors has emerged as an essential bulwark protecting drug access for Cubans, even as the U.S. blockade has intensified in recent years.
The event also included participation from practicing Cuban oncologists, who held working discussions with facility leadership to align production priorities with real-time clinical needs on the ground. This direct input ensures that output from the plant will directly address the most pressing care demands facing patients across the country.
Far from being an isolated infrastructure milestone, the restart of the AICA Laboratories plant stands as a clear illustration of the coordinated mission that unites Cuba’s biotechnology sector and public health system: to guarantee access to essential medications for all citizens, regardless of external pressures. For a country grappling with externally induced supply shortages, every treatment produced at this expanded facility represents more than just medicine – it is a testament to Cuban public health sovereignty, a source of hope for thousands of patients and families, and a reaffirmation of the state’s longstanding commitment to the universal right to health.